Amgen Stock Dives
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...
Goldman Sachs analysts removed Amgen (AMGN) from the firm’s US Conviction List as part of its monthly update.Don't Miss our Black Friday ...
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Amgen posted earnings that were better than expected last month. Because Amgen stock has heavy institutional ownership, ...
Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.
Since its establishment in 1990, the ABE program has now reached over 1 million students across 16 countries, helping to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback